小胶质细胞活化与自发性ARIA-E及脑脊液抗Aβ自身抗体水平的关联
该纵向病例系列研究评估脑淀粉样血管病相关炎症(CAA-ri)患者ARIA-E急性期及皮质类固醇治疗后小胶质细胞活化的空间分布与时间变化,采用多模态MRI、脑脊液抗Aβ自身抗体检测及11C-PK11195 PET。结果显示小胶质细胞活化与ARIA-E空间共定位,且合并AD与严重CAA者活化程度更高;脑脊液抗Aβ自身抗体在急性期升高、治疗后显著下降并与临床缓解平行。
要点
- 11C-PK11195 PET显示小胶质细胞活化与ARIA-E空间共定位,为体内证据。
- 合并AD与严重CAA者ARIA-E及小胶质细胞活化程度高于单纯CAA者。
- 脑脊液抗Aβ自身抗体可用于诊断、预后及治疗反应监测。
核心结论
- 研究提供首个体内11C-PK11195 PET证据,提示小胶质细胞活化与脑脊液抗Aβ自身抗体升高且合并AD和CAA患者的ARIA-E范围和严重程度相关。
- 作者认为脑脊液抗Aβ自身抗体检测是有前景的诊断、预后及治疗反应生物标志物,可帮助指导未来临床实践和治疗管理决策。
研究设计与样本
- 纵向病例系列研究,纳入CAA-ri(即单克隆抗体降Aβ免疫治疗中所见医源性ARIA-E的自发变异型)患者。
- 采用多模态多参数MRI按经验证的评分系统量化CAA和ARIA-E严重程度,检测脑脊液抗Aβ自身抗体和AD生物标志物,并以11C-PK11195 PET评估活化小胶质细胞。
- 评估时间点为ARIA-E(亚)急性期就诊时及皮质类固醇治疗后随访时。
主要发现
- 在(亚)急性期,发现小胶质细胞活化的局灶峰值与ARIA-E的空间共定位程度高于与慢性年龄相关白质改变影像异常的空间共定位程度。
- 合并AD和严重CAA的患者,其ARIA-E严重程度及相应小胶质细胞活化幅度均高于仅有CAA的患者。
- 就诊时所有患者脑脊液抗Aβ自身抗体均高,治疗后随访时明显下降,与急性症状临床缓解、ARIA-E严重程度减轻及小胶质细胞活化减少平行。
临床怎么用
- 作者认为脑脊液抗Aβ自身抗体检测是有前景的诊断、预后和治疗反应生物标志物,可帮助指导未来临床实践和临床试验中的治疗与管理决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Amyloid-related imaging abnormalities suggestive of vasogenic edema or sulcal effusion (ARIA-E) are the most common adverse events complicating Alzheimer disease (AD) immunotherapy with anti-β-amyloid (Aβ) monoclonal antibodies. ARIA-E can also occur spontaneously in cerebral amyloid angiopathy-related inflammation (CAA-ri), a rare autoimmune encephalopathy associated with increased CSF levels of anti-Aβ autoantibodies. Although the pathophysiologic mechanisms of ARIA-E remain to be fully elucidated, experimental evidence from ex vivo studies suggests that gantenerumab and aducanumab enable microglial activation. However, the in vivo evidence for a direct association between neuroinflammation and ARIA-E in patients with high CSF anti-Aβ (auto)antibody levels has never been demonstrated. METHODS: The spatial distribution and temporal variations of microglial activation associated with levels of anti-Aβ autoantibodies at (sub)acute presentation of ARIA-E and after corticosteroid therapy were evaluated in a longitudinal case series of patients with CAA-ri, the spontaneous variant of the iatrogenic ARIA-E reported in Aβ-lowering immunotherapy with monoclonal antibodies. Multimodal and multiparametric MRI was used for CAA and ARIA-E severity quantification, according to validated scoring system; CSF testing for anti-Aβ autoantibodies and AD biomarkers; 11C-PK11195 PET for activated microglia. RESULTS: At (sub)acute presentation, we found focal peaks of microglial activation having a greater spatial colocalization with ARIA-E compared with chronic age-related white matter change imaging abnormalities. The severity of ARIA-E and the magnitude of the associated microglial activation were greater in patients having AD and severe CAA concomitant disease compared with patients having CAA only. CSF anti-Aβ autoantibodies at presentation were high in all patients and markedly decreased at posttreatment follow-up, in parallel with clinical resolution of acute symptoms, reduced ARIA-E severity, and reduced microglial activation. DISCUSSION: Our findings extend the current notion of ARIA-E by providing the first in vivo 11C-PK11195 PET evidence for an association between microglial activation and the magnitude and severity of ARIA-E in patients with increased CSF concentration of anti-Aβ autoantibodies and comorbid AD and CAA disease. Our results highlight CSF testing for anti-Aβ autoantibodies as a promising diagnostic, prognostic, and therapy response biomarker to help guide future treatment and management decisions in real clinical practice and clinical trials.
引用
- Piazza F, Caminiti SP, Zedde M, et al. Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies. Neurology. 2022. PMID: 35940900. doi:10.1212/WNL.0000000000200892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。